German Merck pins hopes on strong 2019

16 October 2018

After what chief executive Stefan Oschmann (pictured above) said had been a “challenging year” for Germany’s Merck KGaA (MRK: DE), the company is targeting a return to profitable growth in 2019.

Merck has predicted sustainable growth next year with respect to the key figures of net sales, earnings before interest, taxes, depreciation and amortization and earnings per share.

That is the headline message being reported to analysts and investors on Tuesday at Merck’s Capital Markets Day, where Merck confirmed its expectations for full-year business performance in 2018 as communicated in the announcement of half-year results.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK